Optonicus Competitors

Neuralink is a neurotechnology company building a generalized input/output platform for the brain. Our work has the potential to restore autonomy to those with unmet medical needs and fundamentally transform how humans interact with the world. Our core technology is an implantable brain-computer interface with ultra-thin, flexible electrode threads placed precisely by a surgical robot, enabling high-bandwidth, bidirectional interaction with neural signals. We’ve received multiple FDA Breakthrough Device designations and are conducting clinical trials around the world. Trial participants are exploring how our implant could enhance their daily lives — controlling digital devices like computers and smartphones, operating physical devices like robotic arms and wheelchairs, and translating thought directly into speech and text. Developing brain-computer interfaces is an interdisciplinary challenge, and we’re looking for exceptional talent across engineering, science, and operations. Explore opportunities to contribute to our mission at neuralink.com/careers.

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.

The RNS® System is an award-winning technology developed and manufactured in Silicon Valley that has been recognized for its innovation. Similar to a pacemaker that monitors and responds to heart rhythms, the RNS System is the world's first and only medical device that can monitor and respond to brain activity. NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. The company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.